Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple
and in some ways conflicting. The treatment algorithm usually includes different types of …

Thus, the task of writing Guidelines or Expert Consensus documents covers not only the
integration of the most recent research, but also the creation of educational tools and …

Background—Treatment options for pulmonary arterial hypertension target the prostacyclin,
endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor …

Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …

Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …

Background Pulmonary hypertension (PH) comprises a group of complex and heterogenous
conditions, characterised by elevated pulmonary artery pressure, and which left untreated …

Background—Sildenafil was recently approved for the treatment of pulmonary arterial
hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5) inhibitors in …